RareStone Group news

RareStone announced that RareStone and Biogen are named the winner of the Golden Snail Award 2022. Sponsored by the Chinese Organization for Rare Disorders, the prestigious Golden Snail Award is the firs

The narcolepsy drug Wakix can now be prescribed to patients in China with urgent unmet medical needs
 
BOSTON, Mass., and Boao, Hainan, China, May 07, 2021 – Citrine Medicine, a China-based rare disease therapeutics company, today announced that the narcolepsy therapy Wakix^® (pitolisant) has been approved by the Health Commission and Medical Products Administration of Hainan Province for its Named Patient Program (NPP). Through this pr

• RareStone Group provided the first batch of donations to the foundation.

December 18th, during the 2021 China Conference on Rare Diseases in Beijing, the China Alliance for Rare Diseases (CHARD) and the Chinese Red Cross Foundation (CRCF) jointly initiated the "Rare Disease Mutual Assistance Fund." The "Rare Disease Mutual Aid Fund" is dedicated to improving rare disease awareness, supporting patient assistance, physician training, and rare disease-rel

• RareStone to seek marketing authorization for IMCIVREE to treat obesity due to biallelic POMC, PCSK1 and LEPR deficiencies and Bardet-Biedl and Alström syndromes in mainland China, Hong Kong and Macau –

BOSTON, December 2, 2021 -- RareStone Group, a rare disease focused company aiming to establish the first rare disease ecosystem in China, Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at devel

Holdings Limited (Tencent),based in Shenzhen,China,signed a strategic collaboration memorandum to develop a service ecosystem focused on rare disease patients in China. The combined effort will promote education of rare disease,focus social awareness on rare disease,and improve accessibility of medical information and services for rare disease by working together to provide innovative digital solutions to benefit rare disease patients.

Through this strategic cooperation,RareS

Collaboration to focus on establishing supply chain and securing distribution channels for delivering rare disease therapies to patients across China

BOSTON, Mass. and SHANGHAI, China, April 19, 2021 – Citrine Medicine, a China-based rare disease therapeutics company, and Sinopharm Group, a Chinese pharmaceutical company, today announced a strategic partnership to accelerate the commercialization of rare disease drugs in China. The two companies will work together to build